Celularity, a New Jersey company developing experimental cancer treatments derived from human placentas, has received the FDA’s blessing to kick off human testing of its lead immunotherapy for cases of COVID-19 disease. The trial, designed to evaluate Celularity drug candidate CYNK-001, will enroll about 100 patients with COVID-19 infection causing pneumonia. Those enrolled will receive […]